ArticlePublic health reports (Washington, D.C. : 1974)2026
Prevalence of Hepatitis C Virus Antibody Testing Across Geography, Time, and Social Vulnerability Among Adults in Florida, 2015-2021.
Article in Public health reports (Washington, D.C. : 1974), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesHepatitis C virus (HCV) screening rates are low in the United States and may be lower among populations experiencing social vulnerability. Little is known about these potential disparities. The current study examined HCV screening prevalence across time, spatial distribution, and social vulnerability among adults in Florida.
methodsWe used data on clinical encounters from the OneFlorida+ data repository to examine the prevalence of HCV screening among adult patients in Florida (N = 1 380 811) from August 1, 2015, through July 31, 2021, by birth cohort (1924-1944, 1945-1965, 1966-1985, and 1986-1997) and risk group (average vs high risk of HCV infection based on behavioral and medical factors). Among patients with a recorded 9-digit zip code (n = 853 965), we conducted spatial analyses, and we used the Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry Social Vulnerability Index (SVI) to examine screening disparities.
resultsThe 1945-1965 birth cohort had the highest likelihood of HCV screening (7.9% among average-risk patients and 24.2% among high-risk patients); those in the 1924-1944 birth cohort had the lowest likelihood (2.0% among average-risk patients and 8.6% among high-risk patients). High-risk patients in almost every geographic area were more likely than average-risk patients to be screened. Screening prevalence was highest in north and northeastern Florida. Among all patients, screening tended to be most likely among those with the highest socioeconomic status and with either the least or most social vulnerability.
conclusionsHCV screening rates were low in Florida across all study years and birth cohorts. Spatial and SVI analyses revealed geographic disparities by region and social vulnerability groups. Interventions are needed to support HCV elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.